Regulators Challenge Zinzino’s Supplement Promotions
Authorities in Sweden and Norway have taken action against Zinzino over allegedly misleading and deceptive marketing practices related to its nutritional supplements.
The regulatory scrutiny focuses on health claims made by Zinzino distributors while promoting the company’s products and business opportunity. Officials argue that certain statements could mislead consumers by suggesting medical benefits that have not been scientifically proven.
Swedish Consumer Agency Bans Specific Marketing Claims
In March 2026, Sweden’s Swedish Consumer Agency prohibited several marketing claims associated with Zinzino products. The decision specifically targeted promotional statements related to the company’s Viva+ Saffron supplement and BalanceOil+ product.
According to the agency, these claims lacked sufficient scientific evidence and could potentially influence consumers to make health decisions based on unsupported information.
Viva+ Saffron Promoted as an Alternative to Antidepressants
Regulators found that some Zinzino distributors promoted the company’s Viva+ Saffron supplement as a substitute for antidepressant medication. Such marketing raised concerns because it could encourage consumers to view a dietary supplement as an alternative to medically prescribed treatments.
The Swedish Consumer Agency concluded that there was no reliable scientific evidence supporting claims that the supplement could replace antidepressant medications.
Pregnancy-Related Claims Draw Regulatory Attention
Authorities also highlighted promotional content involving BalanceOil+. In one example, a distributor reportedly claimed that the product helped her become pregnant.
Regulators determined that the statement implied a health benefit that had not been scientifically verified. As a result, the claim was considered potentially misleading to consumers seeking fertility-related solutions.
